Experience in using levodopa-benserazide
https://doi.org/10.14412/2074-2711-2015-3-93-97
Abstract
Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper considers the mechanism of action, recommended levodopa doses, the time of therapy initiation, and risk factors for motor complications. A few dosage forms of levodopa are currently being used. The results of comparative trials of levodopa-benserazide and levodopa-carbidopa and the clinical experience with Levodopa/Benserazide-Teva are given. An open-label multicenter trial of Levodopa/Benserazide-Teva has shown its high efficacy and good tolerability.
About the Authors
Elena Anatolyevna Katunina
N.I. Pirogov Russian National Research Medical University, Ministry of
Health of Russia
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics,
1, Ostrovityanov St., Moscow 117997
Yu. N. Bezdolnyi
N.I. Pirogov Russian National Research Medical University, Ministry of
Health of Russia
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics,
1, Ostrovityanov St., Moscow 117997
E. A. Malykhina
N.I. Pirogov Russian National Research Medical University, Ministry of
Health of Russia
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics,
1, Ostrovityanov St., Moscow 117997
N. V. Titova
N.I. Pirogov Russian National Research Medical University, Ministry of
Health of Russia
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics,
1, Ostrovityanov St., Moscow 117997
References
1. Salat D, Tololsa E. Levodopa in Treatment of Parkinson’s Disease: Current Status and New Developments. J Parkinsons Dis. 2013 Jan 1;3(3):255-69. doi: 10.3233/JPD-130186.
2. Chaudhuri KR, Glough CG, Sethi KD. Parkinson’s disease. Health Press. 2011;144:11-7.
3. Poewe W, Antonini A. Novel formulation and modes delivery of levodopa. Mov Disord. 2015 Jan;30(1):114-20. doi: 10.1002/mds.26078. Epub 2014 Dec 5.
4. Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002 Feb 26;58(4 Suppl 1):S19-32.
5. Blanchet PJ. The fluctuating parkinsonian patient – clinical and pathophysiological aspects. Can J Neurol Sci. 2003 Mar;30 Suppl 1:S19-26.
6. Verhagen Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord. 2000 Jan;15(1):3-8.
7. Катунина ЕА, Авакян ГН, Титова НВ и др. Леводопа – от создания к новым разработкам. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;(4)110:97-103. [Katunina EA, Avakyan GN, Titova NV, et al. Levodopa – from creation to new developments. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2010;(4)110:97-103. (In Russ.)].
8. Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol. 1992 Feb;49(2):149-51.
9. Голубев ВЛ, Левин ЯИ, Вейн АМ. Болезнь Паркинсона и синдром паркинсонизма. Москва: Медпресс; 1999. 415 с. [Golubev VL, Levin YaI, Vein AM. Bolezn' Parkinsona i sindrom parkinsonizma [Parkinson's disease and Parkinsonian syndrome]. Moscow: Medpress; 1999. 415 p.]
10. Шток ВН, Федорова НВ. Болезнь Паркинсона. Экстрапирамидные расстройства: Руководство по диагностике и лечению. Под ред. В.Н. Штока. Москва: Медпрессинформ; 2002. С. 87-124. [Shtok VN, Fedorova NV. Bolezn' Parkinsona. Ekstrapiramidnye rasstroistva: Rukovodstvo po diagnostike i lecheniyu [Parkinson's Disease. Extrapyramidal disorders: a Guide to diagnosis and treatment]. Shtok VN, editor. Moscow: Medpress-inform; 2002. P. 87-124.]
11. Яхно НН. Современные подходы к лекарственному лечению болезни Паркинсона. Клиническая фармакология и терапия. 1994;(3-4):92-7. [Yakhno NN. Modern approaches to drug treatment of Parkinson's disease. Klinicheskaya farmakologiya i terapiya. 1994;(3-4):92-7. (In Russ.)].
12. Clarke CE, Davies P. Systematic review of acute levodopa and aponorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):590-4.
13. Fahn S; Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42.
14. Kondo T. Levodopa therapy from the neuroprotection viewpoint. J Neurol. 2005 Oct;252 Suppl 4: IV32- IV36.
15. Olanow CW. Levodopa: Effect on cell death and natural history of Parkinson’s disease. Mov Disord. 2015 Jan;30(1):37-44. doi: 10.1002/mds.26119. Epub 2014 Dec 11.
16. Schrag A, Hovris A, Morley D, et al. Young vs old onset Parkinson’s disease: Impact of disease and psychosocial consequences. Mov Disord. 2015 Jan;30(1):37-44. doi: 10.1002/mds.26119. Epub 2014 Dec 11.
17. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3- hydroxytyramine) in human brain: Their behaviour in extrapyramidal system diseases. Klin Wochenschr. 1960 Dec 15;38:1236-9.
18. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord. 2001 Oct;8(2):95-100.
19. Левин ОС, Федорова НВ. Болезнь Паркинсона. Москва: Медпресс-информ; 2012. С. 170-90. [Levin OS, Fedorova NV. Bolezn' Parkinsona [Parkinson's disease]. Moscow: Medpress-inform; 2012. P. 170-90.]
20. Holloway R, Marek K, Biglan K, et al. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.
21. Aquino CC. Clinical spectrum of levodopainduced complications. Mov Disord. 2015 Jan;30(1):80-9. doi: 10.1002/mds.26125. Epub 2014 Dec 8.
22. Kirsch-Darrow L, Fernandez HH, Marsiske M. Dissociating apathy and depression in Parkinson’s disease. Neurology. 2006 Jul 11;67(1):33-8.
23. Сilia R, Akpalu A, Stephen Sarfo F. The modern prelevodopa era of Parkinson disease: insights into motor complications from sub-Suharan Africa. Brain. 2014 Oct;137 (Pt 10):2731-42. doi: 10.1093/brain/awu195. Epub 2014 Jul 17.
24. Thenganatt MA, Jancovic J. Parkinson disease subtypes. JAMA Neurol. 2014 Apr;71(4):499-504. doi: 10.1001/jamaneurol.2013.6233.
25. Ku S, Glass GA. Age of Parkinson’s disease onset as a predictor for the development of diskinesia. Mov Disord. 2010 Jul 15;25(9): 1177-82. doi: 10.1002/mds.23068.
26. Hassan-Baer S, Molchadski I, Cohen OS. Gender effect on time to levodopa-induced dyskinesias. J Neurol. 2011 Nov;258(11): 2048-53. doi: 10.1007/s00415-011-6067-0. Epub 2011 May 1.
27. Lee JY, Cho J, Lee EK, et al. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Mov Disord. 2011 Jan;26(1):73-9. doi: 10.1002/mds.23400. Epub 2010 Oct 13.
28. Schumacher-Schuh AF, Altmann V, Rieck M, et al. Association of common genetic variants of HOMER 1 gene with levodopa adverse effects in Parkinson’s disease. Pharmacogenomics J. 2014 Jun;14(3):289-94. doi: 10.1038/tpj.2013.37. Epub 2013 Oct 15.
29. Fahn S, Oakes D, Shoulson I, et al. Levodopa and progression of Parkinson’s disease. N Engl J Med. 2004 Dec 9;351(24):2498-508.
30. Pakkenberg H, Birket-Smith E, Dupont E, et al. Parkinson’s disease treated with Sinemet or Madopar. A controlled multicenter trial. Acta Neurol Scand. 1976 May;53(5):376-85.
31. Rinne UK, Molsa P. Levodopa with benserazide or carbidopa in Parkinson’s disease. Neurology. 1979 Dec;29(12):1584-9.
32. Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson’s disease. Neurology. 1979 Dec;29(12):1584-9.
Review
For citations:
Katunina E.A., Bezdolnyi Yu.N., Malykhina E.A., Titova N.V. Experience in using levodopa-benserazide. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(3):93-97. (In Russ.) https://doi.org/10.14412/2074-2711-2015-3-93-97
Views: 920
Email this article 